Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder With Urge Urinary Incontinence Clear all
Not listed Early Phase 1 Interventional

Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder With Urgency Incontinence

NCT05099419
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

NCT01294982
View directory record Official record
Conditions
Overactive Bladder
Interventions
AOBO-001, Placebo
Drug
Lead sponsor
American Oriental Bioengineering, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Mobile, Alabama • West Palm Beach, Florida • Newton, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

NCT00196404
View directory record Official record
Conditions
Urinary Incontinence
Interventions
DR-3001a, DR-3001b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

NCT04211831
View directory record Official record
Conditions
Overactive Bladder With Urge Urinary Incontinence
Interventions
URO-902, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
40 Years to 79 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 5, 2026, 6:57 AM EDT
Not listed No phase listed Observational

Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study

NCT04853849
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Pelvic Floor Disorders
Interventions
Not listed
Lead sponsor
Renalis
Industry
Eligibility
40 Years and older · Female only
Enrollment
50 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

SSR240600C Treatment in Women With Overactive Bladder

NCT00564226
View directory record Official record
Conditions
Overactive Bladder
Interventions
SSR240600C, tolterodine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 5, 2026, 6:57 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Not applicable Interventional Results available

FREEOAB Study for Overactive Bladder

NCT04547920
View directory record Official record
Conditions
Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
Interventions
Wearable Bladder Modulation System
Device
Lead sponsor
Avation Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 5, 2026, 6:57 AM EDT
Not listed Not applicable Interventional

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

NCT02577302
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
Device
Lead sponsor
Uro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Not applicable Interventional

rTMS in Overactive Bladder

NCT06198439
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urgency-frequency Syndrome, Urinary Incontinence, Urinary Incontinence, Urge
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BE Technologies Mobile Uroflowmetry Validation Study

NCT04599283
View directory record Official record
Conditions
BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms, BPH Without Urinary Obstruction, BPH Without Urinary Obstruction With Other Lower Urinary Tract Symptoms, Lower Urinary Tract Symptoms, Overactive Bladder, Overactive Bladder Syndrome, Urinary Obstruction, Urinary Incontinence, Urge
Interventions
MenHealth Uroflowmeter
Device
Lead sponsor
BE Technologies Inc
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 5, 2026, 6:57 AM EDT
Not yet recruiting Phase 4 Interventional

A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections

NCT07387315
View directory record Official record
Conditions
Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Bladder Neurogenesis, Urinary Incontinence, Urge, Pelvic Floor Disorders
Interventions
Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection, Sham Mask
Drug · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 5, 2026, 6:57 AM EDT
Completed No phase listed Observational Results available

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions
Intra-detrusor injection of Onabotulinumtoxin-A
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

NCT00862745
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Fesoterodine, Matching Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 5, 2026, 6:57 AM EDT
Terminated Not applicable Interventional

A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

NCT05381116
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urge Incontinence
Interventions
Avation System, Sham Avation System
Device
Lead sponsor
Avation Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Tucson, Arizona • Oak Lawn, Illinois • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

NCT03817931
View directory record Official record
Conditions
Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions
Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
Drug · Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00662909
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
109
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 5, 2026, 6:57 AM EDT
Completed Not applicable Interventional Results available

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

NCT03556891
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
15
States / cities
Downey, California • Redwood City, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 5, 2026, 6:57 AM EDT
Terminated Not applicable Interventional

Group Medical Visits for Latina Women With Urgency Urinary Incontinence

NCT03687164
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urge Incontinence
Interventions
Group Medical Visits
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 5, 2026, 6:57 AM EDT